Trilliant Health

The U.S. health economy is $4.5T – more than the entire GDP of any country in the world other than China – and is projected to grow to $7.7T by 2032 – more than the combined total GDP of Germany and India. What is society’s return on this massive investment? Not much, according to our latest report, the 2024 Trends Shaping the Health Economy.? The 2024 edition of our Trends Shaping the Health Economy Report explores the 8 macro trends that will define the emerging landscape of the U.S. healthcare system and concludes that the winners of healthcare’s negative-sum game will be those who deliver optimal value to their customers. ?? https://lnkd.in/eqEqsPX3

New this month in Compass+ ?? Reports: The 90-page Service Line Intelligence: Cardiology Report analyzes trends impacting the #cardio landscape and includes an interactive data dashboard, a report walkthrough from our Executive Director of Research and a discussion guide. ?? Policy Points: A review of the policy initiatives that dominated 2024 and how they’ll continue to impact health economy stakeholders in the upcoming year. ?? Primer Brief: An in-depth look at how value optimization, as opposed to value maximization, will create a more equitable and efficient health economy. ??Industry Pulse: Conversations with the Chief Planning and Consulting Officer at Bon Secours Mercy Health and Co-Founder and CEO of Octave on the importance of a tailored portfolio strategy and the impact of #virtualcare. ??? Presentation-Ready Slides: Sharable slides featuring new insights on the affordability of healthcare, prescribing volumes for stimulants, provider participation in value-based care and more. Subscribe to Compass+: https://hubs.ly/Q02Z9qc90

While most Americans (82%) still trust #primarycare providers (PCPs) as a source of health information, the high costs of care and undersupply of PCPs can serve as a barrier to solely relying on physicians for direct health advice. Notably, a quarter of Americans report trusting #socialmedia content creators for health information, compared to 52% who report trust in national health authorities. More in #TheCompass.

The #election of Donald Trump as the 47th President of the United States, together with projected Republican control of Congress, could have significant implications for health economy stakeholders. Read this special edition of Counterpoint for insight into these seven strategic healthcare issues: ?? Healthcare #Affordability ?? Site-Neutral Payment ?? Inpatient Only List ?? #PriceTransparency and Value for Money ?? Rising Prescription Drug Costs ?? Food and Drug Administration #FDA ?? Regulation of Competition

The current state of U.S. physician supply is characterized by factors such as #burnout, an aging workforce, diversified employment opportunities and earlier retirements, resulting in a shortage of several provider types and physician specialties. In analyzing #hematologist and #oncologist supply in CBSAs with populations over 1M, 20 CBSAs have a population-based surplus of physicians, while 36 CBSAs have a population-based shortage, based on national-level Association of American Medical Colleges (AAMC) benchmarks. More in #TheCompass.

If you are promoting #ValueBasedCare as the panacea to America’s septic healthcare system, then you are like one of the characters in The Wizard of Oz. You lack either the heart to tell the American public the truth about the dramatic changes required to save the healthcare system or the brains to do the 3rd-grade math to know that #VBC programs cannot save the day or the courage to do what is necessary to transform the system. Closing your eyes, clicking your heels and thinking that shared risk models will save #Medicare enough money to bend the healthcare cost curve is a dream. In that case, you are part of the problem, not part of the solution.?More in #Counterpoint.

Unlike countries with organizations that evaluate both the clinical and cost-effectiveness of new #prescriptiondrugs during the approval process, such as the U.K.’s National Institute for Health and Care Excellence (NICE), U.S. regulators do not evaluate cost-effectiveness and accessibility. Notably, over 80% of the drugs approved in the U.S. since 2020 are not recommended by NICE, suggesting that many drugs are not providing value commensurate to their cost, even though the U.S. pays 2.7X more for these drugs than the U.K. pays. Ultimately, the benefits of an innovation cannot be fully realized if it is disconnected from affordability and access.?More in #TheCompass. ?

?? Stepped away from our computers and spent some time building new houses for our community with Habitat for Humanity of Greater Nashville. Thank you to all of the team members who helped us make a positive impact!

Despite years of value-based care experimentation, its long-term viability as a strategy to reduce costs while improving quality remains in question. As of 2022, only 25.4% of U.S. healthcare payments flowed through value-based payment models, with #MedicareAdvantage representing the largest share (38.9%). More in #TheCompass. ?

This past Wednesday, our President and Chief Executive Officer took the stage at HLTH USA to open the #GLP1 Summit and provide his perspective on the landscape of #cardiometabolic disease management. Key takeaways: 1?? Despite spending nearly 2X more on healthcare than peer countries, the health status of Americans is deteriorating. From 2020 to 2050, the percentage of U.S. adults with chronic conditions is projected to increase by 12.4 percentage points.? 2?? Between 2020 and 2022, prescription volumes for GLP-1 medications increased 300%, and in 2021, national spending on #semaglutide (the peptide name for drugs like #Ozempic and #Wegovy)?totaled $10.7B. 3?? The increase in GLP-1 use does not correlate with clinical indication. Just over half of patients taking GLP-1s have a history of type 2 diabetes or have an associated medical visit with their prescription. Explore more?research on GLP-1s and metabolic health: https://lnkd.in/eGKQsQSs #bebold #healthcare #healthinnovation #futureofhealth #HLTH?